OraSure Technologies' stock up 3.7% after investor threatens "adversarial path" over buyout bid.
ByAinvest
Monday, Aug 25, 2025 12:39 pm ET1min read
OSUR--
The investor's offer was an all-cash deal, valuing the medical device maker between $3.50 and $4.00 per share. This offer was made by healthcare entrepreneur Ron Zwanziger, along with a prominent investor and others, in June. The board of OraSure rejected the proposal without entering discussions. The company has not yet responded to Reuters' request for comment.
OraSure Technologies, known for its COVID-19 rapid tests, has been facing challenges in the market. The company reported a Q2 2025 earnings call transcript indicating revenue outlooks and product launches, including a new proteomics product and a manufacturing transition [2].
References:
[1] https://seekingalpha.com/news/4488900-orasure-gains-on-report-investor-threatens-adversarial-path-on-buyout
[2] https://seekingalpha.com/news/4488900-orasure-gains-on-report-investor-threatens-adversarial-path-on-buyout
OraSure Technologies rose 3.7% after an investor threatened a potential "adversarial path" if the board continues to resist his buyout offer. The investor offered a takeout deal for the company but was rebuffed by the board. The investor warned that he would pursue an adversarial path if the board does not engage in a collaborative discourse.
OraSure Technologies (NASDAQ: OSUR) saw a 3.7% increase in its stock price following a threat from an investor who made a takeout offer for the company. The investor, who has not been named, warned that if the board continues to resist the offer, he may pursue an "adversarial path." The investor's letter, reported by Reuters, stated that if the board is not willing to engage in a collaborative discussion, he would consider all available alternatives [1].The investor's offer was an all-cash deal, valuing the medical device maker between $3.50 and $4.00 per share. This offer was made by healthcare entrepreneur Ron Zwanziger, along with a prominent investor and others, in June. The board of OraSure rejected the proposal without entering discussions. The company has not yet responded to Reuters' request for comment.
OraSure Technologies, known for its COVID-19 rapid tests, has been facing challenges in the market. The company reported a Q2 2025 earnings call transcript indicating revenue outlooks and product launches, including a new proteomics product and a manufacturing transition [2].
References:
[1] https://seekingalpha.com/news/4488900-orasure-gains-on-report-investor-threatens-adversarial-path-on-buyout
[2] https://seekingalpha.com/news/4488900-orasure-gains-on-report-investor-threatens-adversarial-path-on-buyout

Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet